Pfizer India this week launched two products, Sutent and Medrol in Sri Lanka. Sutent is for the treatment of two rare but life-threatening forms of cancer and will be available in strengths of 12.5 mg, 25 mg and 50 mg while Medrol Tablets are for the treatment of inflammatory disorders when conventional therapy is unsatisfactory or during acute exacerbations of certain chronic diseases. Medrol tablets will be available in 4mg and 16 mg tablets. Hemas Pharmaceuticals (Pte) Ltd will be the prime distributor of these brands in Sri Lanka.
Speaking about the launch, Kewal Handa, Managing Director, Pfizer India said, “We are very excited about our strategy to fortify and grow the business in Sri Lanka .The launch of these innovative drugs is a harbinger of our scale-up plans for the country. Over the next three years we intend to launch several key products in therapeutic areas such cardiovascular, pain and anti-infectives.
” Sanjeewa Samaranayake, Managing Director, Hemas Pharmaceuticals (Pvt) Ltd., said that the launch of these two products further strengthens Pfizer’s presence in Sri Lanka. “With Pfizer’s long-standing and unblemished reputation in the global pharmaceutical industry, I am confident that together we will continue to have a greater presence in this country”. |
E-mail